Which molecular abnormality, when overexpressed, guides targeted therapy in many breast cancers?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards

From $24.99Unlock all

Study for the Clinical Decision-Making (CDM) Cases Part I Test. Engage with challenging scenarios and questions, complete with hints and explanations for better understanding. Prepare thoroughly for your exam!

Multiple Choice

Which molecular abnormality, when overexpressed, guides targeted therapy in many breast cancers?

In breast cancer, HER2 overexpression identifies tumors that respond to targeted anti-HER2 therapy. When the HER2 gene is amplified, the receptor drives excessive growth signaling, but this same overexpression makes the cancer vulnerable to drugs like trastuzumab and other anti-HER2 agents, improving outcomes. Other options reflect different concepts: BRCA1 mutation status relates to DNA repair and is treated with PARP inhibitors in mutation-containing tumors; estrogen receptor positivity guides endocrine therapy; ALK rearrangements are not a common driver in breast cancer. The direct targeted-fixation in many breast cancers is HER2 overexpression.

Which molecular abnormality, when overexpressed, guides targeted therapy in many breast cancers?

Study for the Clinical Decision-Making (CDM) Cases Part I Test. Engage with challenging scenarios and questions, complete with hints and explanations for better understanding. Prepare thoroughly for your exam!

Which molecular abnormality, when overexpressed, guides targeted therapy in many breast cancers?

Get the latest from Passetra